Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US76029N1063
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00L8Z22R1
REPL
Replimune Group Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Replimune Group Inc
ISIN
US76029N1063
TICKER
REPL
MIC
XNAS
REUTERS
REPL.OQ
BLOOMBERG
REPL US
Fri, 25.07.2025       Replimune Group
US76029N1063

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Replimune Group
US76029N1063

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Replimune investors under the federal sec...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Replimune Group
US76029N1063

NEW YORK, July 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting f...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune or the “Company”) (NASDAQ: REPL). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions o...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Replimune Group
US76029N1063

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal securities laws. If you invested in Replimune, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/replimune-group-class-a...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.07.2025       Replimune Group
US76029N1063

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from allegations that Replimune may have issued materially misleading business information to the investing public. So What: If you purchased Replimune secur...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.07.2025       Replimune Group
US76029N1063

WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.06.2025       Replimune Group
US76029N1063

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.06.2025       Replimune Group
US76029N1063

- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions -...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Replimune Group
US76029N1063

•  BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 11.04.2025       Replimune Group
US76029N1063

WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.03.2025       Replimune Group
US76029N1063

WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.02.2025       Replimune Group
US76029N1063

WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2024 and provided a business update....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       Replimune Group
US76029N1063

WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.01.2025       Replimune Group
US76029N1063

WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.12.2024       Replimune Group
US76029N1063

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.11.2024       Replimune Group
US76029N1063

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public offering price of $13.00 per share. In addition, in lieu of com...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.11.2024       Replimune Group
US76029N1063

WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securi...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Replimune Group
US76029N1063

WOBURN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2024 and provided a business update....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sat, 09.11.2024       Replimune Group
US76029N1063

Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 30.10.2024       Replimune Group
US76029N1063

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Sun, 15.09.2024       Replimune Group
US76029N1063

Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.08.2024       Replimune Group
US76029N1063

Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanoma Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combinat...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.08.2024       Replimune Group
US76029N1063

WOBURN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2024 and provided a business update....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.06.2024       Replimune Group
US76029N1063

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.06.2024       Replimune Group
US76029N1063

Primary endpoint data shows 12-month overall response rate (ORR) of 33.6%...
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.05.2024       Replimune Group
US76029N1063

WOBURN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2024 and provided a business update....
Read more
Replimune Group
Technical Analysis Termsheets Terminal
Permalink